The Biotech Growth Trust PLC (BIOG) Fair Value & Analysis
Financial Services · GB · Market cap 313M GBX
Fair value as of: Jul 15, 2026
From 13 valuation models · updated today
Fair value updated Jul 15, 2026 — revised from £0.1600 to £20.51 (+12,718.8%) since Jun 26, 2026. Share price +21.9% over the past month.
Price vs Fair Value (12 months)
12‑month range £7.95 – £16.50 · fair‑value band £15.38 – £25.64 · the £16.00 price screens below the £20.51 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
The Biotech Growth Trust PLC (BIOG) currently trades at £16.00, while our model-based Fair Value estimate is £20.51 — implying the stock looks roughly 28.2% undervalued today. We read business quality at 85/100 (high quality), in the Financial Services sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
It earns a return on equity of -7.0%. Net debt stands at £12.3M. The stock trades on a trailing P/E of 2.9. Fundamentals as of Jul 15, 2026
Our scenario range runs from £15.38 (bear case) to £25.64 (bull case); at £16.00, the current price sits within that range. For context, the median of 10 Financial Services peers we cover trades at 90% fair-value upside — at 28%, BIOG screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
The Biotech Growth Trust PLC is a closed ended equity mutual fund launched by Frostrow Capital LLP. It is co-managed by OrbiMed Capital LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the biotechnology sector. The fund invests in stocks of companies across all market capitalizations. It employs fundamental analysis to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index. It was previously known as Finsbury Emerging Biotechnology Trust PLC. The Biotech Growth Trust PLC was formed on May 20, 1997 and is domiciled in the United Kingdom.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
The Biotech Growth Trust PLC reported revenue of £137M in FY2026 versus −£210M in FY2022. Reported net income was £130M in FY2026.
Is BIOG fairly valued? → Check now
Similar stocks
10 more Asset Management stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Fondul Proprietatea SA FP | $0.0420 | $0.0800 | +90% |
| The Schiehallion Fund Limited MNTN | $2.27 | $4.54 | +100% |
| BlackRock, Inc BLK | $1,019 | $597.61 | -41% |
| Blackstone Inc BX | $118.55 | $61.04 | -49% |
| BH Macro Limited BHMU | $0.0442 | $0.0900 | +104% |
| Investor AB INVEB | kr 377.85 | kr 1,417 | +275% |
| BioPharma Credit PLC BPCR | $0.0095 | $0.0200 | +111% |
| Brookfield Corporation BN | $44.13 | $11.09 | -75% |
| KKR & Co KKR | C$21.40 | C$5.96 | -72% |
| Brookfield Asset Management Ltd BAM | $45.70 | $32.37 | -29% |
Explore undervalued stocks
More undervalued Financial Services stocks →
Frequently asked questions
Is The Biotech Growth Trust PLC (BIOG) undervalued?
What is the fair value of BIOG?
What is the quality score of BIOG?
What is the net profit margin of BIOG?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Tell me when The Biotech Growth Trust PLC reaches its Fair Value
Just your email — and we'll notify you when the price and Fair Value of The Biotech Growth Trust PLC materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.